Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy
In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to p...